MRC1 and breast cancer: The anti‐metastatic effect of MACTIDE‐V may be explained by the reduction of “M2‐like” TAM (here CD206+MHCII−), cells with a major role in breast cancer metastasis.[47] A similar upregulation of pro‐inflammatory and anti‐tumoral markers was observed in vitro in BMDM after MACTIDE‐V treatment, further strengthening the idea that this PDC modulates macrophages toward an M1‐like or a mixed M1‐M2 phenotype.